| Description | Milatuzumab (MEDI-115) is a humanized monoclonal antibody against CD74. Milatuzumab promotes the production of free radical oxygen and the loss of mitochondrial membrane potential, reduces CD20/CD74 aggregates and cell adhesion, and induces cell death. |
| In vitro | Milatuzumab（5 μg/mL；8-48小时）增强了MCL细胞系和原发性患者肿瘤细胞的死亡[1]。在Jeko、Mino和SP-53细胞中，Milatuzumab（5 μg/mL；0.5-2小时）介导的细胞毒性部分依赖于ROS产生和线粒体跨膜电位的丧失[1]。Milatuzumab（5 μg/mL；4小时）抑制了NF-κB通路并诱导了凋亡。凋亡机制与caspase切割、Bcl-2家族成员紊乱或自噬诱导无关[1]。 |
| In vivo | 通过每3天一次的腹腔注射，以每天15 mg/kg的剂量给药，milatuzumab显著提高了携带Jeko癌细胞的女性SCID小鼠的存活率。此外，在这个小鼠模型中，Milatuzumab与Rituximab显示出了协同作用[1]。 |
| Synonyms | hLL1, MEDI-115 |
| molecular weight | N/A |
| CAS | 899796-83-9 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Alinari L, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41. |